Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Jonathan M. Meyer, MD, provides insight on initiating long-acting injectables (LAIs) in the schizophrenia treatment plan early and how to discuss this with patients.
Lindsay Galvin Rauch and Xavier Amador, PhD, tackle the importance of the DSM-5 revisions on helping to educate clinicians on diagnosing and treating patients with anosognosia.
Lindsay Galvin Rauch and Xavier Amador, PhD, tackle the importance of the DSM-5 revisions on helping to educate clinicians on diagnosing and treating patients with anosognosia.
Lindsay Galvin Rauch and Xavier Amador, PhD, address how to incorporate the LEAP (Listen-Emphasize-Agree-Partner) approach in collaborative care as a way to improve relationships.
Lindsay Galvin Rauch and Xavier Amador, PhD, address how to incorporate the LEAP (Listen-Emphasize-Agree-Partner) approach in collaborative care as a way to improve relationships.
Lindsay Galvin Rauch interviews Xavier Amador, PhD, on defining and diagnosing anosognosia as it relates to severe mental illnesses, such as schizophrenia.
Lindsay Galvin Rauch interviews Xavier Amador, PhD, on defining and diagnosing anosognosia as it relates to severe mental illnesses, such as schizophrenia.